Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology.

Lambert LJ, Challa AK, Niu A, Zhou L, Tucholski J, Johnson MS, Nagy TR, Eberhardt AW, Estep PN, Kesterson RA, Grams JM.

Dis Model Mech. 2016 Oct 1;9(10):1169-1179. Epub 2016 Jul 28.

2.

Decreased protein S-palmitoylation in dorsolateral prefrontal cortex in schizophrenia.

Pinner AL, Tucholski J, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH.

Schizophr Res. 2016 Nov;177(1-3):78-87. doi: 10.1016/j.schres.2016.01.054. Epub 2016 Feb 11.

3.

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, L├╝cke K, Wikman H, Jackson S, Brychta N, von Ahsen O, Schumann C, Krahn T, Pantel K.

Clin Cancer Res. 2016 May 1;22(9):2197-206. doi: 10.1158/1078-0432.CCR-15-1416. Epub 2015 Dec 14.

4.

Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.

Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Keilholz U, Fusi A.

Target Oncol. 2015 Mar;10(1):77-84. doi: 10.1007/s11523-014-0318-9. Epub 2014 May 15.

PMID:
24824730
5.

Evolutionarily conserved pattern of AMPA receptor subunit glycosylation in Mammalian frontal cortex.

Tucholski J, Pinner AL, Simmons MS, Meador-Woodruff JH.

PLoS One. 2014 Apr 8;9(4):e94255. doi: 10.1371/journal.pone.0094255. eCollection 2014.

6.

Nck-mediated recruitment of BCAP to the BCR regulates the PI(3)K-Akt pathway in B cells.

Castello A, Gaya M, Tucholski J, Oellerich T, Lu KH, Tafuri A, Pawson T, Wienands J, Engelke M, Batista FD.

Nat Immunol. 2013 Sep;14(9):966-75. doi: 10.1038/ni.2685. Epub 2013 Aug 4.

PMID:
23913047
7.

N-linked glycosylation of cortical N-methyl-D-aspartate and kainate receptor subunits in schizophrenia.

Tucholski J, Simmons MS, Pinner AL, McMillan LD, Haroutunian V, Meador-Woodruff JH.

Neuroreport. 2013 Aug 21;24(12):688-91. doi: 10.1097/WNR.0b013e328363bd8a.

8.

Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia.

Drummond JB, Tucholski J, Haroutunian V, Meador-Woodruff JH.

Schizophr Res. 2013 Jun;147(1):32-38. doi: 10.1016/j.schres.2013.03.010. Epub 2013 Apr 6.

9.

Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia.

Tucholski J, Simmons MS, Pinner AL, Haroutunian V, McCullumsmith RE, Meador-Woodruff JH.

Schizophr Res. 2013 May;146(1-3):177-83. doi: 10.1016/j.schres.2013.01.031. Epub 2013 Feb 23.

10.

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, Detloff PJ, Lesort M.

Exp Neurol. 2012 Sep;237(1):78-89. doi: 10.1016/j.expneurol.2012.05.015. Epub 2012 Jun 12.

11.

Transglutaminase 2: a molecular Swiss army knife.

Gundemir S, Colak G, Tucholski J, Johnson GV.

Biochim Biophys Acta. 2012 Feb;1823(2):406-19. doi: 10.1016/j.bbamcr.2011.09.012. Epub 2011 Oct 10. Review.

12.

Transglutaminase 2 protects against ischemic stroke.

Filiano AJ, Tucholski J, Dolan PJ, Colak G, Johnson GV.

Neurobiol Dis. 2010 Sep;39(3):334-43. doi: 10.1016/j.nbd.2010.04.018. Epub 2010 May 6.

13.

TG2 protects neuroblastoma cells against DNA-damage-induced stress, suppresses p53 activation.

Tucholski J.

Amino Acids. 2010 Jul;39(2):523-32. doi: 10.1007/s00726-009-0468-8. Epub 2010 Jan 29.

PMID:
20112034
14.

The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.

Ruan Q, Tucholski J, Gundemir S, Johnson Voll GV.

Int J Clin Exp Med. 2008;1(3):248-59. Epub 2008 Jun 30.

15.

Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.

Filiano AJ, Bailey CD, Tucholski J, Gundemir S, Johnson GV.

FASEB J. 2008 Aug;22(8):2662-75. doi: 10.1096/fj.07-097709. Epub 2008 Mar 28.

16.

Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage.

Tucholski J, Roth KA, Johnson GV.

J Neurochem. 2006 Apr;97(2):582-94. Epub 2006 Mar 15.

17.

Transglutaminases in neurodegenerative disorders.

Bailey CD, Tucholski J, Johnson GV.

Prog Exp Tumor Res. 2005;38:139-57. Review. No abstract available.

PMID:
15746534
18.

Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis.

Robitaille K, Daviau A, Tucholski J, Johnson GV, Rancourt C, Blouin R.

Cell Death Differ. 2004 May;11(5):542-9.

19.

Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death.

Milakovic T, Tucholski J, McCoy E, Johnson GV.

J Biol Chem. 2004 Mar 5;279(10):8715-22. Epub 2003 Dec 11.

20.
21.

Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.

Lesort M, Lee M, Tucholski J, Johnson GV.

J Biol Chem. 2003 Feb 7;278(6):3825-30. Epub 2002 Nov 27.

22.
23.

Does tissue transglutaminase play a role in Huntington's disease?

Lesort M, Chun W, Tucholski J, Johnson GV.

Neurochem Int. 2002 Jan;40(1):37-52. Review.

PMID:
11738471
24.
25.

Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.

Chun W, Lesort M, Tucholski J, Faber PW, MacDonald ME, Ross CA, Johnson GV.

Neurobiol Dis. 2001 Jun;8(3):391-404.

PMID:
11442349
26.

Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.

Chun W, Lesort M, Tucholski J, Ross CA, Johnson GV.

J Cell Biol. 2001 Apr 2;153(1):25-34.

27.

Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells.

Tucholski J, Lesort M, Johnson GV.

Neuroscience. 2001;102(2):481-91.

PMID:
11166134
28.

Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.

Lesort M, Tucholski J, Zhang J, Johnson GV.

J Neurochem. 2000 Nov;75(5):1951-61.

29.

Tissue transglutaminase: a possible role in neurodegenerative diseases.

Lesort M, Tucholski J, Miller ML, Johnson GV.

Prog Neurobiol. 2000 Aug;61(5):439-63. Review.

PMID:
10748319
30.
31.

Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling.

Zhang J, Tucholski J, Lesort M, Jope RS, Johnson GV.

Biochem J. 1999 Nov 1;343 Pt 3:541-9.

32.
33.

Growth factor regulation of cell growth and proliferation in the nervous system. A new intracrine nuclear mechanism.

Stachowiak MK, Moffett J, Maher P, Tucholski J, Stachowiak EK.

Mol Neurobiol. 1997 Dec;15(3):257-83. Review.

PMID:
9457702
34.

Nuclear accumulation of fibroblast growth factor receptors in human glial cells--association with cell proliferation.

Stachowiak EK, Maher PA, Tucholski J, Mordechai E, Joy A, Moffett J, Coons S, Stachowiak MK.

Oncogene. 1997 May 8;14(18):2201-11.

35.

MmeI, a class-IIS restriction endonuclease: purification and characterization.

Tucholski J, Skowron PM, Podhajska AJ.

Gene. 1995 May 19;157(1-2):87-92.

PMID:
7607532
36.

Atypical DNA-binding properties of class-IIS restriction endonucleases: evidence for recognition of the cognate sequence by a FokI monomer.

Skowron P, Kaczorowski T, Tucholski J, Podhajska AJ.

Gene. 1993 Mar 15;125(1):1-10. Erratum in: Gene 1994 Apr 8;141(1):151.

PMID:
8166773

Supplemental Content

Loading ...
Support Center